Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

US Patent 10494433 · Granted Dec 3, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

NKp46 binding agents2025
Treatment of cancer2025
Compound that specifically binds to KIR3DL2 for use in the treatment of peripher2024
Treatment regimens using anti-NKG2A antibodies2024
Treatment regimens using anti-NKG2A antibodies2024
Treatment of peripheral T cell lymphoma2024
Treatment of peripheral T cell lymphoma2024
Methane and emissions reduction system2023
Neutralization of inhibitory pathways in lymphocytes2023
Neutralization of inhibitory pathways in lymphocytes2023
System and methodology for high pressure alternate path2022
NKp46 binding agents2022